Home › Funds › Vivo Capital, LLC › ERAS
Vivo Capital, LLC position in ERAS
ERASCA INC · Health Care
Vivo Capital, LLC reported holding 4,020,619 shares of ERAS (ERASCA INC) in its Q3 2026 13F filing — a position valued at US$58.9M, representing 6.69% of its reported portfolio and ranking #3 among its reported holdings. Vivo Capital, LLC has disclosed ERAS holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Vivo Capital, LLC's ERAS position evolved
Vivo Capital, LLC first disclosed a stake in ERAS in Q2 2024 at 6,756,756 shares (US$15.9M). The position peaked in Q1 2026 at 12,151,480 shares, worth US$196.6M. Across 10 filings, Vivo Capital, LLC increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 5 time(s). The most recent filing (Q3 2026) shows 4,020,619 shares valued at US$58.9M — a reduction of -106,793 shares quarter over quarter.. Notable position changes include a 37% increase in Q3 2025 (shares rose 71% over the following quarter), a 31% increase in Q1 2026 (shares rose 13% over the following quarter), a 66% trim in Q2 2026 (shares fell 20% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 6.76M | $15.95M | New |
| Q3 2024 | 6.76M | $18.45M | Hold |
| Q4 2024 | 6.76M | $16.96M | Hold |
| Q1 2025 | 6.76M | $9.26M | Hold |
| Q2 2025 | 6.76M | $8.58M | Hold |
| Q3 2025 | 9.27M | $20.22M | Add |
| Q4 2025 | 9.27M | $34.50M | Hold |
| Q1 2026 | 12.15M | $196.61M | Add |
| Q2 2026 | 4.13M | $75.61M | Reduce |
| Q3 2026 | 4.02M | $58.94M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ERAS and 13F data
ERAS (ERASCA INC) is a Health Care company. 75 other funds we track also report a position in ERAS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$457.5M), RTW INVESTMENTS, LP (US$328.8M), Venrock Adviser, LLC (US$327.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ERAS
- Frazier Life Sciences Management, L.P. 24.98M sh · $457.55M · Q2 2026
- RTW INVESTMENTS, LP 17.95M sh · $328.78M · Q2 2026
- Venrock Adviser, LLC 17.89M sh · $327.78M · Q2 2026
- Logos Global Management LP 12.15M sh · $222.59M · Q2 2026
- Siren, L.L.C. 13.20M sh · $193.48M · Q3 2026
- Paradigm Biocapital Advisors LP 9.55M sh · $174.96M · Q2 2026
- ARCH Venture Management, LLC 7.09M sh · $129.92M · Q2 2026
- Cormorant Asset Management, LP 6.00M sh · $109.92M · Q2 2026
- Affinity Asset Advisors, LLC 5.25M sh · $96.18M · Q2 2026
- a16z Capital Management, L.L.C. 2.86M sh · $52.44M · Q2 2026
- Soleus Capital Management, L.P. 2.70M sh · $49.46M · Q2 2026
- SAMLYN CAPITAL, LLC 2.26M sh · $41.35M · Q2 2026
More on Vivo Capital, LLC
FAQ
How long has Vivo Capital, LLC held ERAS?
Vivo Capital, LLC has disclosed ERAS holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
What is Vivo Capital, LLC's current position in ERAS?
As of Q3 2026, Vivo Capital, LLC holds 4.02M shares of ERAS (ERASCA INC), valued at $58.94M, representing 6.69% of its reported portfolio and ranking #3.
Has Vivo Capital, LLC been buying or selling ERAS?
In the latest 13F filing (Q3 2026), Vivo Capital, LLC reduced its position in ERAS. The position peaked in Q1 2026 at 12.15M shares.
Which other funds hold ERAS?
Other major institutional holders of ERAS include Frazier Life Sciences Management, L.P., RTW INVESTMENTS, LP, Venrock Adviser, LLC, among 75 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.